James V. Caruso
2021
In 2021, James V. Caruso earned a total compensation of $2.2M as President and Chief Executive Officer at Cellectar Biosciences, a 112% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $156,750 |
|---|---|
| Option Awards | $1,472,000 |
| Salary | $522,500 |
| Total | $2,151,250 |
Caruso received $1.5M in option awards, accounting for 68% of the total pay in 2021.
Caruso also received $156.8K in non-equity incentive plan and $522.5K in salary.
Rankings
In 2021, James V. Caruso's compensation ranked 5,771st out of 12,415 executives tracked by ExecPay. In other words, Caruso earned more than 53.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,771 out of 12,415 | 54th |
Division Manufacturing | 2,447 out of 5,505 | 56th |
Major group Chemicals And Allied Products | 1,061 out of 2,375 | 55th |
Industry group Drugs | 946 out of 2,096 | 55th |
Industry Pharmaceutical Preparations | 679 out of 1,546 | 56th |
Source: SEC filing on April 29, 2022.
Caruso's colleagues
We found three more compensation records of executives who worked with James V. Caruso at Cellectar Biosciences in 2021.
News
Cellectar Biosciences CEO James Caruso's 2023 pay jumps 34% to $2M
April 26, 2024
Cellectar Biosciences CEO James Caruso's 2021 pay jumps 112% to $2.2M
April 29, 2022
Cellectar Biosciences CEO James Caruso's 2020 pay rises 9% to $1M
May 13, 2021
Cellectar Biosciences CEO James Caruso's 2019 pay jumps 21% to $934K
April 28, 2020
Cellectar Biosciences CEO James Caruso's 2018 pay falls 23% to $770K
April 29, 2019